Trials Sponsors Conditions Drugs Pricing

Conditions

Overweight or Obesity Type 2 Diabetes

Keywords

NA-931, obesity, Type 2 Diabetes, Biomed Industries, Inc

Outcome Measures

Primary Outcomes (1)

Incidence of Treatment-Emergent Adverse Events in NA-931 participants
To evaluate the safety and tolerability of NA-931
28 days

Secondary Outcomes (2)

Maximum observe drug concentration (Cmax) of NA-931
28 days
Effect of a High-Fat Meal on Plasma Concentration of NA-931
28 days

Study Arms (2)

Participant Group/Arm- NA-931

EXPERIMENTAL

Experimental: NA-931 Capsule of NA-931 intervention

Drug: NA-931

Participant Group/Arm- Placebo

PLACEBO COMPARATOR

Placebo Comparator: Placebo Capsule of placebo

Drug: Placebo

Interventions

NA-931Drug

NA-931 is a quadruple receptor agonist for weight loss

Also known as: NA-931 is a quadruple receptor agonist

Participant Group/Arm- NA-931

PlaceboDrug

Placebo of NA-931

Also known as: Placebo of NA-931

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Participants 18-65 years old, inclusive
BMI of 25 - 40, inclusive

Sponsors & Collaborators

Biomed Industries, Inc.
Industrylead

Study Sites (2)

Biomed Industries Pty Limited- Clinical Testing Site 1

Camperdown, New South Wales, 2050, Australia

Biomed Industries, Pty Limited Testing Site 2

Parkville, Victoria, 3052, Australia

MeSH Terms

Conditions

OverweightObesityDiabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases

Study Officials

Lloyd Tran, PhD
Biomed Industries, Inc.
STUDY DIRECTOR

Enrollment

74 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: RANDOMIZED
Masking: TRIPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 24, 2024

First Posted

September 27, 2024

Study Start

May 6, 2024

Actual (reported)

Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Participant Group/Arm- NA-931

Participant Group/Arm- Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Participant Group/Arm- NA-931

Participant Group/Arm- Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations